Print（PDF/190KB） Mar. 02, 2026 Finances
Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma -
Sumitomo Pharma Co., Ltd. (the "Company") resolved at its Board of Directors meeting held on March 2, 2026, to formulate “Boost 2028 - Accelerating Strong Sumitomo Pharma -” as its growth strategy for FY2026 through FY2028 and to revise “Reboot 2027 - Reboot for a Strong Sumitomo Pharma -,” which was announced in May 2025.
The Board of Directors also resolved at the same meeting to file a shelf registration statement in Japan for the issuance of new shares, which was announced today.
For further details of the filing of shelf registration statement for the issuance of new shares, please refer to the press release. (Announcement of Filing of Shelf Registration Statement for Issuance of New Shares)
1. Background to the Formulation of “Boost 2028”
After experiencing a significant decline in business performance in FY2023, the Company implemented fundamental structural reforms that enabled the V-shaped recovery in FY2024. Under “Reboot 2027” announced in May 2025, the Company has positioned FY2025 to FY2027 as a critical phase, marked by key milestones including strengthening its earnings base through substantial sales growth of the three key products and establishing a robust business foundation for early-stage products in the fields of regenerative medicine/cell therapy and oncology. Throughout this period, the Company has focused its operations on rebuilding the value‑creation cycle.
This has led to a record‑high core operating profit of 107 billion yen in FY2025 forecast, expecting to achieve the Reboot 2027 financial targets ahead of schedule. While maintaining disciplined SG&A and R&D expenses management to accelerate regrowth following the V-shaped recovery, the Company has formulated "Boost 2028 - Accelerating Strong Sumitomo Pharma -," which outlines the growth strategy for FY2026 through FY2028.
2．Financial KPIs under “Boost 2028”
The KPIs for FY2028 are as follows.
| Sales of ORGOVYX® and GEMTESA® | With two blockbuster drugs, over 350 billion yen in FY2028 |
|---|---|
| ROE | 10% or more (FY2026-FY2028) |
| Equity ratio |
Over 50% at an early stage Recover to positive net cash |
|
R&D expenses Including regenerative medicine/cell therapy business (Equity-method affiliate) |
Allocate over 180 billion yen cumulatively from FY2026 to FY2028 while considering ROE |
With regard to shareholder returns, the Company aims for an early resumption of dividends, taking into account the progress of Boost 2028.
3. Key Initiatives under “Boost 2028”
The Company will further strengthen its earnings base by maximizing the value of its focus products, particularly ORGOVYX® and GEMTESA®, through actively highlighting their clinical benefits. Furthermore, to establish its next-generation earnings base, the Company seeks to achieve the fastest feasible launch, focusing resources on priority programs of the two oncology compounds, enzomenib and nuvisertib. The Company will also define the optimal development strategy during “Boost 2028” for maximizing value of the two oncology compounds.
The Company aims to continuously create breakthrough therapies and strengthen its R&D platform through a development strategy prioritizing early identification of objective efficacy signals in patients, focusing on hematological malignancies and neurodegenerative disease including rare neurological disorders. This approach will enable the Company to further enhance pipeline and portfolio for sustainable growth.
“Boost 2028” focuses on the main initiatives for FY2026 through FY2028, and the Company plans to develop a comprehensive growth strategy after defining the strategic direction for the two oncology compounds.
For further details, please refer to the presentation material ( Boost 2028 - Accelerating “Strong Sumitomo Pharma” briefing material ).
- (Note) This document contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
- Note: This press release is a general release regarding the formulation of the growth strategy of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States. Furthermore, the forecasts, projections, expectations, and other forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions or premises. Actual results may differ materially from the projections stated herein due to various known or unknown risks, including economic conditions, that may affect the Company's performance.
Inquiries from the Press